GYNECOLOGIC CANCER: Edited by Gottfried E. KonecnyLatest clinical evidence of maintenance therapy in ovarian cancerWalsh, Christine S.Author Information Department of Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA Correspondence to Christine S. Walsh, MD, Department of Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Suite 160W, Los Angeles, CA 90048, USA. Tel: +1 310 423 5456; e-mail: email@example.com Current Opinion in Obstetrics and Gynecology: February 2020 - Volume 32 - Issue 1 - p 15-21 doi: 10.1097/GCO.0000000000000592 Buy Metrics Abstract Purpose of review To summarize the data supporting the use of maintenance therapy in ovarian cancer treatment. Recent findings Since December 2016, the United States Food and Drug Administration has approved four drugs for six different ovarian cancer maintenance indications based on the results of clinical trials demonstrating efficacy and tolerability. These include antiangiogenesis and poly (adenosine diphosphate-ribose) inhibitors (PARP inhibitors). Four drugs are approved for use in maintenance therapy for recurrent ovarian cancer, including bevacizumab (GOG-0213 and OCEANS), niraparib (NOVA), olaparib (Study 19 and SOLO2) and rucaparib (ARIEL3). Two drugs are approved for use in maintenance therapy in newly diagnosed ovarian cancer, including bevacizumab (GOG-0218) and olaparib (SOLO1). New data were reported at the European Society for Medical Oncology Congress in October 2019 that may lead to the approval of additional strategies in front-line maintenance, including the use of niraparib (PRIMA), veliparib (VELIA) and bevacizumab + olaparib (PAOLA). Summary The landscape of maintenance treatment options for ovarian cancer has been rapidly expanding and continues to evolve as new data emerge. Currently approved strategies include antiangiogenesis and PARP inhibitor treatments. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.